NEW YORK – New research has begun to make a case for both multi-biomarker approaches and multi-timepoint testing as a way to identify more cancer patients who benefit from immunotherapies while saving others who do not from wasted treatment.
In a study published last week in Cell, investigators from Stanford and Memorial Sloan Kettering collaborated to explore a novel combination biomarker approach for immunotherapy response prediction in non-small cell lung cancer.